Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 03:02:59 2024-05-23 EDT			5-day change	1st Jan Change
3.01 ^EUR	+0.17%		-24.41%	-54.93%

05-21	CARMAT : Invest Securities remains Buy, lowers its target	CF
05-17	Oddo BHF Cuts Carmat PT, Affirms Neutral Rating	MT

CARMAT Appoints Pascale d’Arbonneau as Chief Financial Officer

December 12, 2018 at 12:00 pm

CARMAT announced the appointment of Pascale d’Arbonneau as Chief Financial Officer. Before joining CARMAT, Pascale d’Arbonneau was Executive Director of the Econocom International B.V. (EIBV) family office.

Latest news about CARMAT

CARMAT : Invest Securities remains Buy, lowers its target	05-21	CF
Oddo BHF Cuts Carmat PT, Affirms Neutral Rating	05-17	MT
CARMAT : price target lowered by Oddo BHF	05-17	CF
Carmat Raises EUR16 Million for Ongoing Operations, Clinical Trial	05-17	MT
Carmat: 16 million euros successfully raised	05-17	CF
Carmat: launches a fund-raising campaign of around €15 million	05-16	CF
Carmat: progress in ongoing clinical study	05-06	CF
CARMAT Continues to Build on Its Momentum in the EFICAS Study	05-06	CI
Carmat SA Reiterates Sales Guidance for the Year 2024	05-06	CI
Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Carmat: final agreement with creditors	03-25	CF
Carmat Secures Two-year Extensions for Bank Loans	03-25	MT
CARMAT Announces a Final Agreement with All Its Financial Creditors on New Repayment Terms for Its Bank Loans	03-22	CI
Carmat: up sharply, broker upgrades to 'buy	02-01	CF
CARMAT : Invest Securities upgrades to 'buy'.	02-01	CF
Oddo BHF Keeps Carmat at Neutral, Cuts PT	01-29	MT
France’s Carmat Secures EUR17 Million via Capital Raise; Shares Fall	01-29	MT
CARMAT : price target lowered by Oddo BHF	01-29	CF
Carmat: capital increase completed	01-29	CF
Carmat SA announced that it has received ?16.5186 million in funding	01-28	CI
CARMAT : Invest Securities advises to subscribe	01-18	CF
Transcript : Carmat SA - Special Call	01-17
Carmat: launches a capital increase	01-17	CF
Carmat SA announced that it expects to receive ?15.000002 million in funding	01-16	CI
Carmat: has passed the 50-implant milestone	01-15	CF

Chart CARMAT

Duration

Period

More charts

Company Profile

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for CARMAT

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.005 EUR

Average target price

12.98 EUR

Spread / Average Target

+331.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
CARMAT	-54.93%	94.81M
STRYKER CORPORATION	+12.01%	128B
SMITH & NEPHEW PLC	-5.89%	11.26B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+6.26%	9.28B
GLAUKOS CORPORATION	+35.53%	5.42B
AXONICS, INC.	+8.68%	3.45B
ENOVIS CORPORATION	-8.89%	2.8B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-10.68%	2.1B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-10.77%	1.98B
DOUBLE MEDICAL TECHNOLOGY INC.	-26.31%	1.71B

Medical Devices & Implants